Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoringÁgueda Molinos-Quintana, Josè Antonio Pérez-Simón, Víctor Galán‐Gómez et al.|Frontiers in Immunology|2024Cited by 21
Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoringÁgueda Molinos-Quintana, Josè Antonio Pérez-Simón, Anna Alonso‐Saladrigues et al.|Frontiers in Immunology|2024Cited by 1